Other ·Strong evidence ·Reviewed May 2026
Universal methyl donor involved in over 100 methylation reactions in the body.
The bottom line
Evidence rating strong. Most-documented uses: mood support, joint health, liver health. 20 sources indexed (1993–2024), with 16 interaction records on file.
Core mechanism
Donates methyl groups for DNA methylation, neurotransmitter synthesis (dopamine, serotonin, norepinephrine), phospholipid metabolism, and glutathione production.17,5
Take on empty stomach; enteric coating essential; refrigerate
Dosing protocol
Enteric coated to survive gastric acid. Can trigger mania in bipolar; screen carefully.
Ranked by evidence and value.
Real-world pricing across three quality tiers. Assumes Enteric-Coated SAMe.
Assumes 400-1,600 mg/day. Vendor basis: NOW/iHerb, Vitacost, Life Extension, and Amazon marketplace; higher-dose enteric tablets drive premium pricing. Updated 2026-05-28.
How much you'd eat to match a supplemental dose.
SAMe is made in the body from methionine and ATP; methionine foods such as eggs, fish, meat, Brazil nuts, and sesame seeds do not provide SAMe directly.
Dose: 400-1,600 mg daily
Timing: Morning on an empty stomach
Clinical dose evidence: PMID 38423354.
What to test, the optimal window inside the conventional range, and how long a response takes.
SAMe (S-adenosylmethionine, 400 to 1600 mg per day) supports methylation and may modestly lower homocysteine when paired with adequate B12, folate, B6. Also studied for depression and osteoarthritis.17,2
Take on empty stomach for absorption. SAMe is enteric-coated to survive gastric acid. Monitor mood; can trigger mania in bipolar individuals.
Where this appears in the symptom-to-supplement map, ranked by relevance.
SAMe participates in methylation pathways relevant to mood, though it can be activating.1,2
Use caution in bipolar-spectrum illness unless guided clinically.
SAMe is a methyl donor involved in neurotransmitter and joint metabolism, and some older trials suggest it may ease pain and mood symptoms in fibromyalgia.5,17
Do not combine with SSRIs, SNRIs, or other serotonergic agents without clinician oversight due to serotonin syndrome risk; use only as supportive care.
Evidence-based stacks that include it, with the exact dose and timing each one uses.
SAMe is the body's principal methyl donor and supports synthesis of monoamine neurotransmitters and phospholipids. Trials suggest an adjunctive mood benefit, but it is serotonergic and must not be combined with other serotonergic agents without clinician oversight.5,17
SAMe increases serotonin synthesis. Combined with SSRIs: serotonin syndrome and/or manic switch risk. 9/11 bipolar patients developed mania on SAMe.
Recommendation: Do NOT combine without close psychiatric supervision. Risk of mania especially high in patients with bipolar disorder.
SAMe is the universal methyl donor; methylcobalamin supports the methionine cycle that regenerates SAMe.
Recommendation: Combining supports methylation status, useful in depression and homocysteine management. Pair with methylfolate for full cycle support.
SAMe has serotonergic and mood-elevating activity that can add to MDMA's serotonin release, increasing the risk of serotonin excess when the two are combined.
Recommendation: Do not combine. Seek medical advice, and watch for agitation, sweating, tremor, or rapid heartbeat as signs of serotonin excess.
Both SAMe and 5-HTP independently elevate serotonin activity, so combining them stacks two pro-serotonergic mechanisms. Case literature documents treatment-emergent hypomania and a theoretical risk of serotonin excess (agitation, insomnia, tremor, GI distress, and in extreme cases serotonin syndrome) when over-the-counter SAMe and 5-HTP are used together, especially at the higher end of typical dosing (SAMe 400 to 1600 mg/day, 5-HTP 150 to 800 mg/day). The risk is amplified if any prescription serotonergic agent is also on board.
Recommendation: Do not start both supplements at full dose simultaneously. If a clinician supports using them together, introduce one at a time, start low (for example SAMe 200 to 400 mg/day and 5-HTP 50 to 100 mg/day), and titrate slowly while watching for agitation, restlessness, insomnia, racing thoughts, sweating, or tremor. Avoid the combination entirely if you take any SSRI, SNRI, MAOI, triptan, tramadol, or other serotonergic medication. Stop and seek care if signs of serotonin excess appear.
Supplemental SAMe increases flux through the methionine cycle and generates homocysteine downstream. Vitamin B6 is the cofactor that allows the transsulfuration arm to dispose of that homocysteine. With sufficient B6 (alongside folate and B12), the pathway runs cleanly and homocysteine is converted to cysteine and glutathione. The pairing is a beneficial synergy that supports methylation balance, which is why clinical SAMe trials have specifically co-administered B6, folate, and B12 to study homocysteine handling.
Recommendation: If taking SAMe (commonly 400 to 1200 mg/day), ensure adequate vitamin B6 status (a typical maintenance dose is around 1.3 to 2 mg/day from diet or a B-complex, with supplemental forms often 10 to 25 mg/day; avoid chronic high-dose B6 above roughly 100 mg/day due to neuropathy risk). For best methylation support, B6 is most effective when paired with folate and B12. No separation in timing is needed; daily co-administration is appropriate. Those with cardiovascular risk or known elevated homocysteine should have homocysteine monitored.
SAMe (S-adenosylmethionine) has demonstrated antidepressant properties and increases serotonergic, noradrenergic, and dopaminergic activity. When combined with sertraline, SAMe may excessively potentiate serotonergic signaling, increasing the risk of serotonin syndrome.
Recommendation: Use SAMe with sertraline only under direct medical supervision. Do not self-prescribe this combination. If prescribed together as adjunctive therapy, start SAMe at low doses and watch for signs of serotonin excess.
SAMe increases serotonergic activity through multiple mechanisms. Combined with fluoxetine's potent and long-lasting SERT inhibition, the risk of serotonin excess increases. While some research has explored SAMe as SSRI augmentation, this should only occur under medical supervision.
Recommendation: Do not self-prescribe SAMe while taking fluoxetine. If being considered as adjunctive therapy, this must be done under close psychiatric supervision with gradual dose titration.
SAMe has serotonergic properties that may potentiate escitalopram's effects. While some psychiatrists use SAMe augmentation in treatment-resistant depression, the combination requires careful monitoring due to the risk of excessive serotonergic stimulation.
Recommendation: Only combine SAMe with escitalopram under direct psychiatric supervision. Do not add SAMe on your own. Start at low doses if prescribed together, and monitor for signs of serotonin excess.
SAMe has antidepressant effects and evidence of serotonergic involvement, including 5-HT1A pathway activation in preclinical work. Buspirone also acts at 5-HT1A receptors, so the combination may increase restlessness, sweating, tremor, diarrhea, insomnia, or other serotonin-excess symptoms in susceptible people. Risk is higher when SAMe is added to other antidepressants or serotonergic drugs.
Recommendation: Do not start SAMe on top of buspirone without discussing the dose and monitoring plan with your prescriber. If the combination is used, start low, avoid adding other serotonergic products, and stop SAMe if you develop new agitation, tremor, sweating, diarrhea, or muscle jerks. Seek urgent care for fever, confusion, rigidity, or clonus.
SAMe has antidepressant and monoamine-modulating activity. Duloxetine increases serotonin and norepinephrine signaling, so adding SAMe may increase the risk of serotonin toxicity or mood activation. Watch for agitation, sweating, tremor, diarrhea, clonus, fever, insomnia, or manic symptoms.
Recommendation: Avoid starting SAMe with duloxetine unless the prescriber managing duloxetine approves and monitors the combination. Seek urgent care for clonus, high fever, severe agitation, confusion, or seizure.
SAMe has antidepressant and monoamine-modulating activity. Venlafaxine increases serotonergic signaling, especially at lower and moderate doses, and also increases norepinephrine at higher doses. Adding SAMe may increase the risk of serotonin toxicity or mood activation.
Recommendation: Do not add SAMe to venlafaxine without prescriber approval. Stop the supplement and seek urgent care for clonus, high fever, severe agitation, confusion, seizure, or rapidly escalating manic symptoms.
SAMe has antidepressant activity and serotonergic relevance, while tramadol inhibits serotonin reuptake and is a known serotonin syndrome risk drug. A published case report describes toxicity when SAMe was combined with the serotonergic antidepressant clomipramine, so adding SAMe to tramadol is a clinically plausible serotonergic stacking risk. Symptoms can include restlessness, sweating, tremor, diarrhea, fever, clonus, confusion, and seizure.
Recommendation: Avoid SAMe while taking tramadol unless your prescriber specifically approves and monitors the combination. Do not add SAMe for mood support during tramadol treatment. Seek urgent care for high fever, muscle rigidity, clonus, severe agitation, or seizure.
Numbered references. Citations throughout the page link here.
23 trials (N=2183) assessed SAMe for depression as monotherapy, adjunctive, and comparator; evidence shows promising but mixed efficacy.
14 trials (1,522 subjects): no significant difference in depression with SAMe vs comparison when used as monotherapy or adjunctive therapy.
Baden KER, McClain H, Craig E et al.. S-Adenosylmethionine (SAMe) for Central Nervous System Health: A Systematic Review. Nutrients. 2024
SAMe was among the pharmacological interventions evaluated; it reduced pruritus and liver enzymes in intrahepatic cholestasis of pregnancy, though UDCA showed more consistent benefits.
Nutrients involved in one-carbon metabolism, including SAMe pathway components (folate, B12, betaine), significantly influenced global DNA methylation status in adults.
Cuomo A, Beccarini Crescenzi B, Bolognesi S et al.. S-Adenosylmethionine (SAMe) in major depressive disorder (MDD): a clinician-oriented systematic review. Annals of general psychiatry. 2020
Zhang Y, Lu L, Victor DW et al.. Ursodeoxycholic Acid and S-adenosylmethionine for the Treatment of Intrahepatic Cholestasis of Pregnancy: A Meta-analysis. Hepatitis monthly. 2016
SAMe significantly improved total bilirubin and AST levels in chronic liver disease with few adverse events (primarily mild GI complaints).
Four trials (656 patients) showed small standardized mean difference of -0.17 for pain; inconclusive due to small trial size and quality issues.
Williams AL, Girard C, Jui D et al.. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clinical and investigative medicine. Medecine clinique et experimentale. 2005
Frezza M. [A meta-analysis of therapeutic trials with ademetionine in the treatment of intrahepatic cholestasis]. Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna. 1993
Zhu SS, Dong Y, Gan Y et al.. [Efficacy and safety of ademetionine for treatment of drug-induced liver disease in children]. Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology. 2010
Thompson MA, Bauer BA, Loehrer LL et al.. Dietary supplement S-adenosyl-L-methionine (AdoMet) effects on plasma homocysteine levels in healthy human subjects: a double-blind, placebo-controlled, randomized clinical trial. Journal of alternative and complementary medicine (New York, N.Y.). 2009
SAMe (commonly 1000-1200 mg/day) was effective for liver function improvement with favorable safety profile; no serious adverse events reported.
SAMe shows promise for major depressive disorder with limited evidence as monotherapy and augmentation; involved in methylation for neurotransmitter synthesis.
Case report describes mania with psychotic features during concomitant SAMe and SSRI use.
Case report documents a manic episode temporally associated with SAMe use.
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack